Prescription Medicine for Men Over 50: What Women Need to Know

Why Women Are Reading a Men's Health Guide

You may be here because your partner was just prescribed testosterone. Or you found finasteride in the bathroom cabinet and are pregnant. Or you are a clinician, a caregiver, or a woman trying to make sense of how his health affects yours. All of those are valid reasons.

This guide covers the major prescription categories for men over 50, what the evidence actually shows, and where the real risks for the women in their lives sit. This is not a male-default clinical rundown. It is a guide written with you in mind.

The Biology of Men After 50: What Is Actually Changing

After age 50, men experience a gradual decline in testosterone of roughly 1 to 2 percent per year, a pattern sometimes called late-onset hypogonadism or, colloquially, andropause. This is not the same hormonal cliff that perimenopause represents for women, but the cumulative effect over a decade is real. By age 60, an estimated 20 percent of men have clinically low testosterone, with some estimates reaching 40 percent depending on the threshold used.

Simultaneously, cardiovascular risk rises sharply. Men over 50 account for a disproportionate share of first myocardial infarction events, and metabolic syndrome becomes more prevalent as visceral fat accumulates and insulin sensitivity declines.

These changes rarely happen in isolation. A man dealing with low energy, poor sleep, and erectile dysfunction at 55 may have overlapping low testosterone, sleep apnea, early type 2 diabetes, and depression, all of which have specific prescription treatments, and all of which affect the household around him.

Why This Matters for Women Specifically

If you are in perimenopause yourself, around ages 45 to 55, you and your partner may be experiencing coinciding hormonal transitions. Research published in Menopause documents that couples navigating simultaneous hormonal changes report lower sexual satisfaction and higher relationship strain than couples where only one partner is affected. Knowing what his prescriptions do, and do not do, helps you both.

Testosterone Replacement Therapy (TRT): The Most Contested Prescription

Testosterone replacement therapy is the most frequently discussed, most frequently misunderstood prescription category for men over 50. Here is what the evidence actually says.

Who Qualifies

Clinical diagnosis of hypogonadism requires two morning serum testosterone measurements below 300 ng/dL plus symptoms: fatigue, reduced libido, loss of muscle mass, depression, or erectile dysfunction. The Endocrine Society 2018 guideline specifies that treatment should not be offered based on age alone or based on a single low reading.

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials funded by the NIH and published in the New England Journal of Medicine in 2016, remain the most rigorous evidence base. In 788 men over 65 with confirmed low testosterone, TRT improved sexual function, mood, and bone density modestly, but showed no cardiovascular benefit and a signal toward increased cardiovascular events in higher-risk men.

Forms and Doses

| Formulation | Typical Dose | Notes | |---|---|---| | Testosterone gel (AndroGel 1%) | 50 mg/day topically | Transfer risk to women and children via skin contact | | Testosterone cypionate injection | 100-200 mg every 1-2 weeks IM | Peaks and troughs more pronounced | | Testosterone undecanoate (Aveed) | 750 mg IM at weeks 0, 4, then every 10 weeks | Requires REMS program, clinic administration | | Testosterone patch (Androderm) | 2-4 mg/day | Skin irritation common |

The Transfer Risk Women Must Know

Testosterone gel transfers to women and children through skin contact. The FDA issued a Black Box warning in 2009 requiring gel products to carry explicit transfer risk labeling. If your partner uses testosterone gel, you should avoid direct skin contact with his application sites, and he should wash his hands and cover treated skin before contact. Women who are pregnant, trying to conceive, or breastfeeding face the highest risk of androgen exposure affecting fetal development.

Monitoring Schedule

Men on TRT require PSA and hematocrit checks at 3 to 6 months, then annually. Polycythemia (high red blood cell count) is the most common laboratory complication, occurring in roughly 5 to 10 percent of treated men. Dose reduction or phlebotomy is the standard response.

Erectile Dysfunction Medications: The PDE5 Inhibitors

Erectile dysfunction affects an estimated 52 percent of men between ages 40 and 70, based on the landmark Massachusetts Male Aging Study. By age 70, the prevalence of complete erectile dysfunction reaches approximately 15 percent.

The Four FDA-Approved Options

Sildenafil (Viagra): 25 to 100 mg taken 30 to 60 minutes before sexual activity. The original key trials showed a response rate of approximately 70 percent versus 22 percent for placebo.

Tadalafil (Cialis): 10 to 20 mg as needed, or 2.5 to 5 mg daily. The daily low-dose option is particularly useful for men who also have lower urinary tract symptoms from benign prostatic hyperplasia.

Vardenafil (Levitra): 10 to 20 mg as needed. Slightly faster onset than sildenafil.

Avanafil (Stendra): 50 to 200 mg, onset as fast as 15 minutes in some men. Fewer drug interactions than older agents.

What Women Need to Understand About PDE5 Inhibitors

These drugs do not create desire. They support blood flow. If erectile dysfunction has a predominantly psychological or relational cause, medication alone is unlikely to resolve it. The American Urological Association guideline recommends that psychological and relationship counseling be offered alongside pharmacotherapy.

PDE5 inhibitors are absolutely contraindicated with nitrate medications (nitroglycerin, isosorbide mononitrate) because the combination can cause life-threatening hypotension. If he uses any nitrate, including recreational poppers (amyl nitrite), PDE5 inhibitors are off the table entirely.

A Note on Purchasing Safely

Counterfeit sildenafil is widespread online. FDA analysis of seized products has found wide variability in actual drug content, including products containing none of the labeled drug or dangerously high doses. Obtaining these medications through a licensed prescriber and a verified pharmacy is not just a formality.

Finasteride and Dutasteride: What Every Woman of Reproductive Age Must Know

Finasteride (Propecia at 1 mg for hair loss, Proscar at 5 mg for benign prostatic hyperplasia) and dutasteride (Avodart at 0.5 mg for BPH) are 5-alpha-reductase inhibitors. They block the conversion of testosterone to dihydrotestosterone (DHT), which drives both prostate growth and male-pattern hair loss.

Pregnancy Contraindication: This Is Categorical

Finasteride is FDA Pregnancy Category X. Even dermal exposure to crushed or broken finasteride tablets can cause abnormalities of the external genitalia in a male fetus. The FDA label states explicitly that women who are pregnant or may become pregnant must not handle crushed or broken tablets.

If you are pregnant, trying to conceive, or breastfeeding and your partner uses finasteride:

• He should not handle the tablets around you without ensuring you have no contact.
• Whole, intact tablets present negligible transfer risk in normal handling, but broken or crushed tablets do not.
• There is no established safe level of finasteride exposure during pregnancy.
• Dutasteride carries the same Category X designation and has a longer half-life (roughly 5 weeks) than finasteride (6 to 8 hours), meaning it persists in semen and body tissues for months after stopping.

The FDA label for dutasteride (Avodart) states that women of childbearing potential should not handle the capsules.

Efficacy Data

In men with BPH, finasteride 5 mg reduces prostate volume by approximately 20 to 30 percent over 6 to 12 months. For androgenic alopecia, finasteride 1 mg prevents further hair loss in approximately 86 percent of men and produces visible regrowth in about 65 percent after two years of use.

Sexual Side Effects: What Partners Experience Too

Finasteride causes sexual side effects in a subset of men, including decreased libido, erectile dysfunction, and ejaculatory disorders, in approximately 3.4 to 15.8 percent depending on the study and outcome measure. A smaller number of men report persistent sexual side effects after stopping the drug, a phenomenon sometimes called post-finasteride syndrome, though the FDA has not formally recognized it as a distinct clinical entity. These effects have direct implications for a couple's sexual relationship.

Cardiovascular Medications: The Prescriptions Most Likely to Actually Save His Life

Cardiovascular disease is the leading cause of death in men over 50. The most commonly prescribed drug classes are statins, ACE inhibitors and ARBs, beta-blockers, and antiplatelet agents. A full clinical review of each is beyond this hub's scope, but the points most relevant to shared household health are worth naming.

Statins

Statins (atorvastatin, rosuvastatin, simvastatin) reduce LDL cholesterol and are recommended by the ACC/AHA guideline for men with 10-year cardiovascular risk above 7.5 percent. The evidence of benefit in men with established cardiovascular disease is among the strongest in pharmacology.

Women in perimenopause and beyond face their own rising cardiovascular risk. If you have not had your own 10-year risk calculated, his diagnosis is a useful prompt to request your own lipid panel. The same ACC/AHA pooled cohort equations apply.

Antihypertensives

ACE inhibitors (lisinopril, ramipril) and ARBs (losartan, valsartan) are first-line for hypertension with concurrent diabetes or chronic kidney disease. Both drug classes are contraindicated in pregnancy due to fetal renal toxicity. If you are pregnant and he uses these medications, no direct risk to you exists from his prescription, but the shared-household knowledge point is worth having.

GLP-1 Receptor Agonists for Men Over 50: Weight and Metabolic Health

Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are now commonly prescribed for men over 50 with obesity or type 2 diabetes. In the STEP 1 trial, semaglutide 2.4 mg weekly produced a mean weight loss of 14.9 percent over 68 weeks versus 2.4 percent for placebo.

Men over 50 with obesity carry excess visceral fat that suppresses testosterone, worsens insulin resistance, and raises cardiovascular risk. Weight loss with GLP-1 agents may improve erectile function and even raise testosterone levels secondarily, by reducing the peripheral aromatization of testosterone to estradiol that occurs in adipose tissue.

Women in the same household who are themselves candidates for GLP-1 therapy may wish to discuss their own eligibility. Wegovy and Zepbound are FDA-approved for weight management in adults with BMI >30 or >27 with a weight-related comorbidity.

GLP-1 medications are not recommended during pregnancy. Women of reproductive age using GLP-1 agents should use reliable contraception, because the mechanism of weight loss does not confer contraceptive protection, and the drugs have not been studied in human pregnancy.

Mental Health Medications: Depression and Anxiety After 50

Depression is underdiagnosed in men over 50, partly because men are less likely to report mood symptoms and more likely to present with irritability, fatigue, or somatic complaints. SSRIs and SNRIs are first-line for major depressive disorder regardless of sex, though the sexual side effect profile (particularly delayed ejaculation and reduced libido) may be more new in men already experiencing age-related sexual changes.

Bupropion (Wellbutrin) is sometimes preferred when sexual side effects are a concern, and it is the only antidepressant approved by the FDA as a smoking cessation aid (under the Zyban label), which is additionally relevant in men over 50 with cardiovascular risk.

If his depression is affecting your relationship, your own mental health, or your household, that is a clinical concern, not merely a personal one. Couples therapy alongside pharmacotherapy has a stronger evidence base than either intervention alone.

Who This Treatment Category Is Right For, and Who Should Wait

Likely Candidates for Evaluation

• Men over 50 with documented low morning testosterone on two separate measurements, plus symptoms
• Men with erectile dysfunction that has not responded to lifestyle change (exercise, alcohol reduction, sleep improvement)
• Men with BPH causing urinary symptoms, confirmed by urologist review
• Men with LDL above 190 mg/dL or 10-year cardiovascular risk above 7.5 percent
• Men with BMI above 30 and type 2 diabetes or metabolic syndrome

When to Slow Down or Reconsider

• Active prostate cancer: testosterone therapy is contraindicated
• Hematocrit above 54 percent before starting TRT: treat polycythemia first
• Unstable cardiovascular disease: PDE5 inhibitors require cardiology clearance
• Men taking nitrates in any form: PDE5 inhibitors are absolutely contraindicated
• Men with untreated severe obstructive sleep apnea: treat the sleep apnea first, as it is a reversible cause of low testosterone

Evidence Gaps: What We Do Not Yet Know

Women have been historically excluded from clinical trials, and the data gap is well documented. Less appreciated is that older men are also underrepresented in trials relative to the age at which many conditions first appear. The TTrials enrolled men over 65, making them more applicable to older men than the many TRT trials that enrolled men in their 40s and 50s. Long-term cardiovascular safety data for TRT beyond 3 to 5 years is sparse. The same is true for GLP-1 agents in men over 70.

As WomanRx medical reviewer Dr. Elena Vasquez, OB-GYN, notes: "Couples rarely come in to discuss his prescription and her health in the same visit. But testosterone gel transfer, finasteride in a pregnancy, or a partner's depression affecting her sleep and stress all have real physiological consequences for women. Those conversations need to happen, and clinicians need to invite them."

Monitoring Summary: What Should Be Checked and When

| Drug / Class | Baseline Tests | Follow-up | |---|---|---| | Testosterone (TRT) | Total T x2, PSA, CBC, LFTs, lipids | At 3-6 months, then annually | | Finasteride / Dutasteride | PSA (note: these drugs halve PSA) | PSA annually (multiply by 2 for true estimate) | | PDE5 inhibitors | Blood pressure, current nitrate use | As needed; annual cardiovascular review | | Statins | Lipid panel, LFTs | Lipid panel at 4-12 weeks, then annually | | GLP-1 agonists | HbA1c, weight, renal function | Every 3 months initially | | Antidepressants | PHQ-9 score, weight, blood pressure | At 4 and 8 weeks, then every 3 months |

Pregnancy, Lactation, and Contraception: The Section Women Must Read

This section covers every drug mentioned above from the perspective of a woman who is pregnant, breastfeeding, or of reproductive age.

Finasteride and Dutasteride: FDA Category X. Do not handle crushed or broken tablets if you are or may be pregnant. Dutasteride persists in semen for months. If pregnancy is possible, discuss this explicitly with your prescriber.

Testosterone gel: Transfer via skin contact can virilize a female fetus. The FDA Black Box warning applies. Avoid gel application sites. Cover skin. Wash hands.

PDE5 inhibitors: Not indicated for use in women. No pregnancy or lactation data of direct relevance, unless you are a woman who has been prescribed one off-label for pulmonary hypertension, in which case that is a separate clinical conversation.

Statins: Contraindicated in pregnancy in women. Not relevant to you directly from his prescription, but a reminder if you are on a statin yourself.

ACE inhibitors / ARBs: Contraindicated in pregnancy due to fetal renal toxicity. Not directly relevant from his prescription.

GLP-1 agonists: Not recommended in pregnancy. Women using GLP-1 agents should use reliable contraception. Rapid weight loss during GLP-1 therapy can restore ovulation in women with PCOS, increasing pregnancy risk in those not using contraception.

Antidepressants (SSRIs/SNRIs): Generally considered lower risk in pregnancy than untreated depression, but the decision requires an individual benefit-risk discussion with your OB or MFM. Paroxetine carries a specific cardiac malformation signal and is generally avoided in the first trimester.